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Inhibition of N-cadherin retards smooth muscle
cell migration and intimal thickening via induction
of apoptosis
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Orest W. Blaschuk, PhD,b and Sarah Jane George, PhD,a Bristol, United Kingdom; and Montreal, Canada
Objectives: Inhibition of vascular smooth muscle cell (VSMC) migration is a potential strategy for reducing intimal
thickening during in-stent restenosis and vein graft failure. In this study, we examined the effect of disrupting the
function of the VSMC adhesion molecule, N-cadherin, using antagonists, neutralizing antibodies, and a dominant
negative, on VSMC migration and intimal thickening. Migration was assessed by the scratch-wound assay of human
saphenous vein VSMCs and in a human saphenous vein ex vivo organ culture model of intimal thickening.
Results: Inhibition of cadherin function using a pan-cadherin antagonist, significantly reduced migration by 53%  8%
compared with the control peptide (n 3; P< .05). Furthermore, inhibition of N-cadherin function with an N-cadherin
antagonist, neutralizing antibodies, and adenoviral expression of dominant negative N-cadherin (RAd dn-N-cadherin),
significantly reduced migration by 31% 2%, 23%  1% and 32%  7% compared with controls, respectively (n 3; P <
.05). Inhibition of cadherin function significantly increased apoptosis by between 1.5- and 3.3-fold at the wound edge.
In an ex vivo model of intimal thickening, inhibition of N-cadherin function by infection of human saphenous vein
segments with RAd dn-N-cadherin significantly reduced VSMC migration by 55% and increased VSMC apoptosis by
2.7-fold. As a result, intimal thickening was significantly suppressed by 54%  14%. Importantly, there was no
detrimental effect of dn-N-cadherin on endothelial coverage; in fact, it was significantly increased, as was survival of
cultured human saphenous vein endothelial cells.
Conclusions:Under the condition of this study, cell-cell adhesion mediated by N-cadherin regulates VSMCmigration via
modulation of viability. Interestingly, inhibition of N-cadherin function significantly retards intimal thickening via
inhibition of VSMC migration and promotion of endothelial cell survival. We suggest that disruption of N-cadherin-
mediated cell-cell contacts is a potential strategy for reducing VSMC migration and intimal thickening. (J Vasc Surg
2010;52:1301-9.)
Clinical Relevance: Intimal thickening occurs in a large number of coronary artery vein grafts, lower extremity vein grafts,
and stented arteries and is therefore a significant clinical problem. Intimal thickening is caused by migration of vascular
smooth muscle cells (VSMC) from the intima to the media where they proliferate. In this study, we have shown that
inhibition of the function of N-cadherin (a cell-cell contact protein) significantly retards VSMC migration and intimal
thickening, while promoting endothelial coverage, and may therefore be clinically useful for treating intimal thickening.Vascular smooth muscle cell (VSMC) migration from
the media to the intima is an important process in athero-
sclerotic plaque development, in-stent restenosis, and vein
graft failure (see review Willis et al1). VSMCs in a healthy
artery normally have low migration rates. In contrast,
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doi:10.1016/j.jvs.2010.05.096VSMC migration is stimulated in response to injury due to
the presence of chemoattractants, remodelling of the extra-
cellular matrix (ECM), and phenotypic changes.2
It has been previously demonstrated that expression of
the cell adhesion molecule, N-cadherin, may increase cell
migration in embryonic development and cancer.3-5 How-
ever, other studies have shown that N-cadherin can inhibit
cell migration in various cell types including astrocytes,
breast carcinoma, and osteosarcoma cells.6-8 These obser-
vations suggest that N-cadherin can either promote adhe-
sion or induce migration depending on the cellular con-
text.5 Studies using VSMCs have yielded contradictory
findings for the role of N-cadherin in VSMC migration.
Jones and colleagues found that N-cadherin was upregu-
lated during intimal thickening in the rat carotid balloon
injury model and promoted VSMC migration in vitro.9 In
contrast, Blindt et al observed that downregulation of
N-cadherin occurred during intimal thickening in the por-
cine femoral balloon injury model and inhibited VSMC
migration in vitro.10 Thus, the role of N-cadherin in VSMC
migration is unclear and requires further investigation.
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tial for VSMC survival.11 We have now investigated
whether VSMC migration was affected by perturbation of
N-cadherin function using an in vitro migration model. In
addition, we assessed whether inhibition of N-cadherin
function retarded intimal thickening by modulation of
VSMC migration and survival using an ex vivo human
saphenous vein model of intimal thickening. We observed
that N-cadherin function perturbation reduced VSMC mi-
gration and intimal thickening, at least in part by reducing
VSMC survival. Importantly, no detrimental effect on en-
dothelial cells was observed.
METHODS
Cell culture. Surplus segments of human saphenous
vein were obtained from patients undergoing coronary
artery bypass surgery (Research Ethical Committee number
04/Q2007/6). VSMCs were grown from these segments
by the explant method of Southgate and Newby.12 VSMCs
were maintained in serum-containing tissue culture media
(Dulbecco’s modified essential media [DMEM] supple-
mented with 100 g/mL of penicillin, 100 IU/mL strep-
tomycin, 2 mML-glutamine and 10% [v/v] fetal calf serum
[FCS]). VSMCs were used at passage 4-8. Three separate
populations of human saphenous vein endothelial cells
were purchased from Promocell and cultured as described
by the supplier.
Effect of N-cadherin function perturbation on
migration. Cells were plated directly on glass coverslips in
24-well plates at 2 104 cells/well. When cells had grown
to confluence, they were injured by rubbing a 1-mL pipette
tip across the layer twice. The culture media was replaced
and 2 mmol/L hydroxyurea was added to inhibit prolifer-
ation. The affect of perturbing N-cadherin function was
investigated by addition of the following agents to the
culture media: 10 g/mL neutralizing anti-N-cadherin
antibody (GC-4; Sigma, Poole, Dorset, UK) or 10 g/mL
nonimmune mouse immunoglobulin G as previously de-
scribed, 9 1 mg/mL of the pan-cadherin antagonist cyclic
peptide (CHAVC, Adherex Technologies Inc) or 1
mg/mL cyclic control peptide (CHGVC), 1 mg/mL of the
N-cadherin antagonist cyclic peptide (CHAVDIC, Adherex
Technologies Inc, NC) or 1 mg/mL cyclic control peptide
(CHGVDIC, Adherex Technologies Inc). Although a dose-
dependent effect on migration was observed with 0.25, 0.5,
and 1 mg/mL of the peptides only, 1 mg/mL the highest
dose is presented. The cells were left to migrate for 24 hours.
In some cases, cells were also treatedwith 2 nmol/L caspase-3
inhibitor (Calbiochem, Nottingham, UK).
Effect of dominant negative N-cadherin (dn-N-
cad) on VSMC migration. A previously described adeno-
virus (RAd dn-N-cad),13 was used to express a dominant
negative form of N-cadherin as previously described and RAd
LacZ, which expresses -galactosidase, was used as a control.
Briefly, VSMCs were plated on glass coverslips in 24 well
plates (2 104 cells/well) and cultured in serum-containing
DMEM for 24 hours. VSMCs were infected with 5, 10, and
50 plaque-forming units (pfu) per cell of RAd dn-N-cad orRAd LacZ in serum-containing DMEM culture media for 18
hours (infection period). The cell layer was wounded twice
using a sterile pipette tip. After washing the cells, they were
cultured in fresh serum-containing DMEM supplemented
with 2 mmol/L hydroxyurea for 24 hours.
Quantification of migration. VSMCs were fixed by
incubation in ice-cold methanol for 10 minutes after the
24-hour incubation period. The coverslips were then air-
dried and stained with hematoxylin, dehydrated, and
mounted with DPX mountant. The migrated distance was
measured at 20 points along the wound edge using the
Media Cybernetics Image Pro Plus version 3 image analysis
system (Data Cell, Maidenhead, UK).
Infection of human saphenous vein. Segments (n 
6) of surgically prepared human saphenous vein not re-
quired for surgery were collected from patients after the
completion of the coronary artery by-pass surgery, as de-
scribed previously.14-18 The vein segment was placed in
wash medium (20 mM Hepes-buffered RPMI 1640 sup-
plemented with 2 mmol/L L-glutamine, 8 g/mL genta-
mycin, 100 IU/mL penicillin, and 100 g/mL streptomy-
cin). The adventitial layer was removed to avoid fibroblast
overgrowth of the intima, and then the vein was bisected
transversely. One segment was infected with RAd dn-N-
cadherin, while the other segment was used as a paired
control infected with RAd LacZ. The vein was infused with
100L of 1.2 1010 pfu/mLRAd dn-N-cadherin or RAd
LacZ, as established previously 16 for a period of 1 hour.
Both infected and control segments were then opened
longitudinally and cut transversely into three 5- to 10-mm
segments. Vein segments were cultured separately endo-
thelial surface uppermost for up to 7 days in culture me-
dium (RPMI 1640 supplemented with 30% FCS, 2 mM
L-glutamine, 100 IU/mL penicillin, 100 g/mL strepto-
mycin, and 10 mol/L bromodeoxyuridine (BrdU), using
a modification of the organ culture method of Pederson
and Bowyer.19 The tissue culture medium was changed
every 2 days. After 3 or 7 days of culture, the vein segments
were washed in phosphate-buffered saline (PBS) and then
fixed in 10% (v/v) formalin in PBS and embedded in
paraffin wax. To evaluate efficiency of adenoviral transgene
expression, paraffin wax sections were stained with X-gal
stain to detect -galactosidase expression as previously
described.16
Immunohistochemical and immunocytochemical
techniques. Cell proliferation was assessed in cultured
cells and paraffin wax sections by immunohistochemistry
for incorporated BrdU, using a monoclonal anti-BrdU
antibody and the protocol described previously.14 The
BrdU index was quantified by counting the percentage of
BrdU-positive VSMCs in the intima of each section. VSMC
migration was estimated by counting the number of cells in
the intima that are not labelled with BrdU and dividing by
the length of the vein segment. This method defines cells
present within the intima that have arisen by migration
alone, and not by migration and proliferation.
Apoptosis was determined by in situ end-labelling
(ISEL) as described previously.14 Briefly, 5-m sections
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and then incubated in reaction buffer containing 0.01 mM
dATP, dCTP, dGTP, and biotin-16-dUTP, 8U/mLDNA
polymerase I (Klenow) large fragment, 50 mM Tris.Cl pH
7.2, 10 mM MgSO4, 0.1 mM DTT for 15 minutes. After
treating with 2% hydrogen peroxide for 10 minutes, slides
were incubated in Extravidin horseradish peroxidase di-
luted 1:200 in 10% FCS in PBS for 30 minutes and then
developed with DAB solution (0.5% 3,3=-diaminobenzidine,
0.03% [v/v] hydrogen peroxide), prior to counterstaining
with hematoxylin. The number of positive neointimal cells
was expressed as a percentage of the total number of
neointimal cells. In addition, the percentage of positive
medial cells in six 0.25 mm2 fields was calculated, and
the average determined. Briefly, cells grown on coverslips
Fig 1. Inhibition of N-cadherin reduces vascular smooth muscle
cell (VSMC) migration. A, Representative images of VSMCs 24
hours after wounding and culture in the presence or absence of 1
mg/mL of the pan-cadherin antagonist (CHAVC) or control
peptide (CHGVC). Quantification of VSMC migration (expressed
as a percentage of the distancemigrated in the presence of the control).
* Indicates significant difference from control, n  4. B, VSMC
migration was measured 24 hours after wounding and treatment
with 1 mg/mL N-cadherin-specific antagonist or control
(CHAVDIC or CHGVDIC), 10 g/mL immunoglobulin G
(IgG) or anti-N-cadherin neutralizing antibody, or infection with
RAd LacZ or dn-N-cad. * Indicates significant difference from
control, † indicates significant difference from IgG control, and
$ indicates significant difference from uninfected and LacZ con-
trols, n  3.were fixed with methanol, while 5-m paraffin sectionswere incubated with 5g/mL proteinase K for 15minutes.
Sections and coverslips were incubated in reaction buffer
containing 0.01 mM dATP, dCTP, dGTP and biotin-
16-dUTP, 8 U/mL DNA polymerase I (Klenow) large
fragment, 50mMTris.Cl pH 7.2, 10mMMgSO4, 0.1mM
DTT for 15 minutes. After treating with 2% hydrogen
peroxide for 10 minutes, coverslips and sections were incu-
bated in Extravidin horseradish peroxidase diluted 1:200 in
10% FCS in PBS for 30 minutes and then developed with
DAB solution (0.5% 3,3=-diaminobenzidine, 0.03% [v/v]
hydrogen peroxide), prior to counterstaining with hema-
toxylin. The number of positive cells at the wound edge
(proximal 200 m) or neointimal cells was expressed as a
percentage of the total number of wound edge or neointi-
mal cells, respectively. In addition, the percentage of posi-
tive medial cells in six 0.25 mm2 fields was calculated and
the average determined.
Endothelial cell coverage was assessed in paraffin wax
sections using immunohistochemistry for QBend10 as pre-
viously described.18 Briefly, endogenous peroxidase was
blocked with 3% hydrogen peroxide prior to incubating
in 20% goat serum for 30 minutes and then QBend10
antibody diluted 1:50 (DAKO, Ely, Cambridgeshire,
UK, M7165) for 60 minutes. Bound antibodies were de-
tected with biotinylated goat antimouse immunoglobulin,
Extravidin-horseradish peroxidase, and DAB solution. The
percentage coverage of the endothelium was measured along
the entire surface of four separate paraffin wax-embedded
sections using the Media Cybernetics Image Pro Plus ver-
sion 3 image analysis system (Data Cell, Maidenhead, UK).
Phosphorylated Akt (pAkt) was quantified in cultured
VSMCs as described previously.20
Quantification of intimal thickening. Transverse
sections (3 m) were stained with Miller’s elastic van
Gieson (EVG), Mayer’s hematoxylin, and eosin. The inti-
mal thickening was quantified using image analysis. Briefly,
the intimal area and length of the vein segments were
measured. The mean intimal thickness was determined by
dividing the intimal area by the length of the vein segment.
Modulation of endothelial cell behavior. The effect
of N-cadherin inhibition on endothelial cell behavior was
examined using 1 mg/mL N-cadherin-specific antagonist
(CHAVDIC) and the control (CHGVDIC) or 10 g/mL
anti-N-cadherin neutralizing antibody and the non-immune
IgG control. To assess proliferation, endothelial cells were
cultured in the presence of 10mol/LBrdU for 24hours and
then immunohistochemistry performed as described previ-
ously.21 To assess migration, endothelial cells were subjected
to scratch wounding as described above for VSMCs. To assess
apoptosis, endothelial cells were cultured in serum-free media
in the presence of theN-cadherin inhibitors or controls for 24
hours and then apoptosis quantified using ISEL as described
previously.14
Statistical analysis. Analysis was performed using
ANOVA for multiple comparisons between groups and
where data were significant Student Newman Keuls, post-
tests were performed to test for significance between two
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Fig 2. Apoptosis occurs because of N-cadherin inhibition. A and B, Representative images to show apoptotic vascular
smooth muscle cells (VSMCs) detected by in situ end labelling (ISEL) (brown) at wound edge after treatment with 10
g/mL immunoglobulin G (IgG: A) or anti-N-cadherin neutralizing antibody (B). Nuclei are stained blue with hematox-
ylin. ISEL-positive cells are brown. Scale bar represents 30m.C, Percentage of apoptotic VSMCs (ISEL positive) at wound
edge 24 hours after wounding and treatment with 10 g/mL immunoglobulin G (IgG) or anti-N-cadherin neutralizing
antibody, or infectionwithRAdLacZor dn-N-cad. * Indicates significant difference from IgGcontrol, † indicates significant
difference from uninfected and LacZ controls, n 3.D, Percentage of apoptotic VSMCs (ISEL positive) at wound edge 24
hours after wounding and treatment with 1 mg/mL pan-cadherin (CHAVC) or N-cadherin-specific antagonists
(CHAVDIC) or controls (CHGVCorCHGVDIC). * Indicates significant difference frompan-cadherin control (CHGVC),
† indicates significant difference fromN-cadherin-specific control (CHGVDIC), n 3.E, Percentage of apoptotic VSMCs
(ISEL positive) at wound edge 24 hours after wounding. * Indicates significant difference from pan-cadherin control
(CHGVC), † indicates significant difference from pan-cadherin antagonist (CHAVC) alone, $ indicates a significant
difference from IgG, and # indicates a significant difference from anti-N-cadherin-neutralizing antibody alone, n 3.
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RESULTS
N-cadherin antagonists inhibit VSMC migration.
The pan-cadherin antagonist (CHAVC: 1 mg/mL) signif-
icantly reduced VSMC migration compared to the control
peptide (CHGVC: 1 mg/mL) (Fig 1, A). Culture in the
presence of the N-cadherin antagonist (1 mg/mL
CHAVDIC) or the neutralizing antibody to N-cadherin
(10 g/mL) significantly reduced VSMC migration com-
pared with the control peptide (CHGVDIC) and non-
immune immunoglobulin control, respectively (Fig 1, B).
Adenoviral overexpression of a dominant negative form of
N-cadherin (dn-N-cad, 50 pfu/cell), which consists only of
the transmembrane and cytosolic regions, similarly signifi-
cantly reduced VSMCmigration in a dose-dependent man-
ner compared with uninfected VSMCs or VSMCs infected
with the control virus LacZ, with 50 pfu/cell reaching
significance (Fig 1, B, only 50 pfu/cell shown).
Similar findings were observed when these experiments
were performed with VSMCs grown on matrix-coated cov-
erslips (Matrigel and collagen type I), data not shown.
Effect of N-cadherin inhibition on VSMC apopto-
sis at the wound edge. We assessed VSMC apoptosis at
the wound edge, since our previous studies revealed that
N-cadherin is an important survival signal for these
cells.11,20 ISEL revealed that apoptosis occurred in approx-
imately 10% of the VSMCs in the proximal 200 m from
the wound edge at 24 hours after wounding (Fig 2, A and
C). Interestingly, VSMC apoptosis at the wound edge was
significantly increased by culture in the presence of the
neutralizing anti-N-cadherin antibody and by expression of
dn-N-cad (Fig 2, B and C). Similarly, the pan-cadherin
antagonist (CHAVC: 1 mg/mL) and N-cadherin-specific
antagonist (CHAVDIC: 1 mg/mL) significantly increased
Fig 3. pAkt is reduced by N-cadherin inhibition. Representative
images and quantification of pAkt in vascular smooth muscle cells
(VSMCs) at the wound edge 24 hours after wounding and treating
with anti-N-cadherin neutralizing antibody or nonimmune immu-
noglobulin control. Scale bar applies to both panels and represents
30m. * Indicates a significant difference from IgG control, n 3.VSMC apoptosis at the wound edge compared to the sameconcentration of the appropriate controls (CHGVC and
CHGVDIC, Fig 2, D). However, in contrast no elevation
in apoptotic rate was observed because of the neutralizing
antibody and peptides at sites further away from the wound
(data not shown). A global increase (17.0%  1.2% vs
7.8%  0.4%) in VSMC apoptosis was observed in VSMCs
infected with the dn-N-cadherin adenovirus, as previously
observed.11
We next determined the effect of inhibiting active
cleaved caspase-3 (an effector caspase involved in apopto-
sis22) on the ability of N-cadherin antagonists to cause
VSMC apoptosis. We observed that the number of ISEL-
positive VSMCs was significantly lower in the presence of a
synthetic caspase-3 inhibitor and either the pan-cadherin
antagonist (CHAVC) or the neutralizing N-cadherin anti-
body compared to peptide or antibody alone (Fig 2, E).
Importantly, there was no significant difference in the
number of apoptotic VSMCs in the controls (CHGVC and
nonimmune immunoglobulin) and those treated with the
caspase-3 inhibitor and pan-cadherin antagonist (CHAVC)
or the neutralizing anti-N-cadherin antibody (Fig 2, E).
However, the presence of the caspase-3 inhibitor did not
restore migration (pan-cadherin antagonist: 270 4 m vs
281 29m; neutralizing antibody: 302 6mvs 271
16 m, n  3).
Phosphorylation of Akt was significantly reduced at the
wound edge in VSMCs treated with the neutralizing N-
cadherin antibody compared with the non-immune immu-
noglobulin control (Fig 3).
Effect of N-cadherin inhibition on intimal thickening.
Segments of human saphenous vein were infected with
adenoviruses to express the reporter gene -galactosidase
and dn-N-cadherin. Expression of the reporter gene was
seen predominantly in the surface cells of the segment at
both 3 and 7 days after infection (Fig 4,A and B); however,
some deeper expression was detected (inset of Fig 4, A).
Expression of dn-N-cadherin significantly reduced VSMC
migration at 7 days but did not affect intimal proliferation
or intimal cell density (Table). VSMC apoptosis was signif-
icantly increased at 7 days in vein segments infected with
RAd dn-N-cadherin (Table and Fig 4, C and D). Intimal
thickness was significantly reduced by expression of dn-N-
cadherin after 7, 10, and 14 days (Fig 4, E-K).
Effect of N-cadherin inhibition on endothelial cells.
QBend10 staining of human saphenous vein organ cultures
at 14 days revealed that endothelial cell coverage was
significantly increased in vein segments infected with RAd
dn-N-cadherin compared to the virus control (RAd LacZ)
(Fig 5). To determine if N-cadherin inhibition affects en-
dothelial cell apoptosis, migration, or proliferation, human
saphenous vein endothelial cells were treated with the
neutralizing N-cadherin antibody or N-cadherin-specific
antagonist (CHAVDIC). Apoptosis assessed by ISEL was
significantly reduced by the neutralizing antibody or N-
cadherin-specific antagonist (CHAVDIC) (Fig 6,A). Iden-
tical results were obtained by immunocytochemistry for
cleaved caspase-3 (data not shown). In contrast, prolifera-
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Fig 4. Intimal thickening is reduced by dn-N-cadherin. Representative detection of -galactosidase protein by X-gal
staining (blue) at 3 days (A) and 7 days (B). Scale bar in A represents 50 m and applies to panels A and B. Inset shows
media X-gal staining. Representative ISEL detection of apoptotic cells (brown) and nuclei are stained blue with
hematoxylin in RAd LacZ-infected control segment (C) and RAd dn-N-cad-infected segment (D) at 7 days. Scale bar
in C represents 20 m and applies to panels C-D. Representative elastin van Gieson staining of RAd LacZ-infected
control segments (E-G) and RAd dn-N-cad-infected segment (H-J) at 7 (E and H), 10 (F and I), and 14 (G and J)
days. Scale bar represents 50 m. (K) Quantification of intimal area in RAd LacZ and RAd dn-N-cad-infected vein
segments. * Indicates a significant difference from RAd LacZ control, n  6.
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N-cadherin perturbation (Fig 6, B and C).
DISCUSSION
Intimal thickening of blood vessels results in a signifi-
cant clinical problem. In particular, approximately 50% of
vein grafts fail within 10 years after implantation.23 Intimal
thickening occurs because of VSMC migration from the
medial layer of the blood vessel to the intima where they
subsequently proliferate and deposit ECM, causing thick-
ening of the intimal layer. Consequently, reduction of
VSMC migration is an attractive target for inhibition of
intimal thickening.
In this study, we examined the effect of inhibiting
N-cadherin function on VSMC migration and intimal
thickening. We observed that inhibiting N-cadherin func-
tion by several methodologies (peptide antagonist, neutral-
izing antibodies, and dominant negative mutant) signifi-
cantly reduced VSMC migration. This appears to be, at
least in part, due to reduced activation of Akt and increased
VSMC apoptosis caused by inhibition of N-cadherin func-
tion. Previously, we showed that N-cadherin is essential for
VSMC survival via activation of Akt,11 and therefore this
study corroborates the pro-survival effect of N-cadherin on
VSMCs. Interestingly, we observed no effect on VSMC
survival in cells located away from the wound edge with the
N-cadherin neutralizing antibody and peptide antagonist.
These observations suggest that these agents do not affect
the viability of VSMCs with established contacts. In con-
trast, dn-N-cadherin did increase apoptosis away from the
wound edge, as this dominant negative disrupts existing
N-cadherin-mediated intercellular junctions.11
Our results confirm the findings of Jones and col-
leagues, who showed that VSMC migration is retarded by
the inhibition of N-cadherin function using a neutralizing
anti-N-cadherin antibody.9 A subsequent study by the
same group has suggested that asymmetric distribution of
N-cadherin is necessary for the establishment of cell polar-
ity during migration and that N-cadherin over-expression
prevents cell polarization during migration.24 However, in
both studies, the effect of inhibiting N-cadherin function
on VSMC apoptosis was not determined.
In contrast to both our study and that of Jones and
Table. Effect of dn-N-cadherin on human saphenous
vein at 7 days after infection
RAd LacZ RAd dn-N-cadherin
Migration (BrdU-ve
intimal cells/mm) 4.0  0.8 1.8  0.3a
Intimal proliferation
(% total) 16  2 21  4
Intimal cell density
(cell/m2  1000) 5.1  0.1 4.9  0.1
Apoptosis (% total) 7.1  1.4 19.2  1.7a
aIndicates a significant difference from RAd LacZ control, n  6.colleagues, Blindt and colleagues previously showed thatVSMCmigration was increased by the neutralizing anti-N-
cadherin antibody.10 Although the reason for this discrep-
ancy is unknown, we suggest two possibilities. First, to
assess migration, Blindt et al used chemotaxis assays rather
than the wound injury model. In the chemotaxis assay,
VSMCs are placed in the chamber as single cells, whereas in
the wound injury model, cell-cell contacts are established
prior to the treatment. Second, the concentration of the
neutralizing anti-N-cadherin antibody was higher in the
study by Blindt et al compared with our study.
To examine whether perturbation of N-cadherin func-
tion in intact segments of vein affected intimal thickening,
we used an established ex vivo human saphenous vein
model of intimal thickening.18,25 In this model, we are able
to effectively overexpress transgenes using adenoviral lume-
nal delivery to segments of human saphenous vein, and we
propose that this approach may be clinically useful for the
overexpression of transgenes that retard intimal thicken-
ing.15-17 Efficient delivery of the transgene was demon-
strated by X-gal staining for expression of -galactosidase
from the LacZ control reporter adenovirus. As in our
previous studies,15-17 expression was predominantly ob-
served at the lumenal surface, although deeper patchy
expression in the medial layer was also detected in approx-
imately 80% of segments. We observed that inhibition of
N-cadherin function using the dominant negative form
significantly increased VSMC apoptosis and retarded
VSMC migration. As a result, intimal thickening was sig-
nificantly reduced. We observed that the dominant nega-
tive N-cadherin did not affect intimal VSMCdensity, which
implies that ECM synthesis was not affected by the domi-
nant negative. Collectively, this demonstrates that inhibi-
tion of N-cadherin function in VSMCs close to the lumenal
surface, which induces apoptosis of these VSMCs, reduces
the number of VSMCs able to migrate to the intima and
cause intimal thickening.
We suggest that overexpression of the dominant nega-
tive form of N-cadherin is a more suitable clinical approach
for the reduction of vein graft intimal thickening than the
peptides. First, we have previously shown potential of this
gene therapy approach for vein grafting failure.17 Addition-
ally, we are cautious of proposingN-cadherin antagonists as
suitable agents for systemic treatment due to potential
adverse side-effects that may ensue as a result of affecting
N-cadherin junctions in other tissues and cell types, eg,
neurones. Consequently, we propose that the N-cadherin
antagonists will need to be delivered locally in a relatively
short time during the surgical procedure. This may be
insufficient exposure to the peptide; however, it is more
than adequate to enable the infection with an adenovirus.17
The adenoviral infection and resultant protein overexpres-
sion will therefore lead to longer bioavailability of the
N-cadherin inhibitor compared with the peptides that will
be quickly washed away. Moreover, the use of the peptide
antagonist for the organ culture experiments and in vivo
would be costly. Our group has also previously shown the
feasibility of using adenoviral gene delivery for the reduc-
tion of in-stent restenosis;26 however, it may be possible to
JOURNAL OF VASCULAR SURGERY
November 20101308 Lyon et aluse N-cadherin peptide antagonist coating of stents to
reduce intimal thickening in stented vessels, but future
studies to assess this are essential.
Since endothelial cell coverage of the vein graft is vital
for the success of the vein graft,27 we examined whether
Fig 5. Endothelial cell coverage is increased by dn-N-ca
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IgGreduced. These data are in contrast to a previous report of
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Volume 52, Number 5 Lyon et al 1309enhanced apoptosis of capillary endothelial cells treated
with the cadherin antagonist,28 but may reflect a difference
in capillary and venous endothelial cells. Consequently, we
conclude that N-cadherin inhibition results in divergent
effects on endothelial cells and VSMCs, which although
not unprecedented, is interesting and warrants future anal-
ysis.
In summary, we have shown that in the context of the
experimental conditions employed in this study, inhibition
of N-cadherin suppresses VSMC migration, at least in part
by induction of apoptosis, both in vitro and ex vivo. Con-
sequently, inhibition of N-cadherin effectively retarded in-
timal thickening in this model. Our findings suggest that
inhibition of N-cadherin-mediated cell-cell contact may be
a therapeutic target for treatment of intimal thickening,
such as that seen during vein graft failure.
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